HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape

EP: 1.Exploring HER2 as a Pan Tumor Biomarker

EP: 2.HER2 in Breast Cancer: Shaping Treatment in Other Solid Tumors

EP: 3.Expert Insights on HER2-Directed ADCs in Breast Cancer

EP: 4.Targeting HER2 Alterations with ADCs in NSCLC

EP: 5.Landscape Surrounding HER2 ADCs in GI Cancers

EP: 6.Emerging Data for HER2 ADCs in Ovarian Cancer

Now Viewing

EP: 7.HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape

EP: 8.HER2 ADCs in Cervical Cancer: A Promising Therapeutic Frontier

EP: 9.Expert Insights on HER2 Testing in Gynecological Cancers

EP: 10.Future Perspectives on HER2 ADCs in Gynecological Cancer

Dr. Ritu Salani discusses the impact of the DESTINY-PanTumor02 trial on the treatment of endometrial cancer, highlighting the promising results and potential implications for clinical practice.

Prior to the DESTINY-PanTumor02 trial, a phase 2 trial investigated the combination of carboplatin, paclitaxel, and trastuzumab followed by trastuzumab maintenance in endometrial cancer. This trial, which used breast cancer IHC expression criteria, showed improved progression-free and overall survival compared to carboplatin and paclitaxel alone. A phase 3 trial was being developed to further explore this approach.

However, the DESTINY-PanTumor02 trial disrupted these plans in a positive way. The trial demonstrated an overall response rate of nearly 60% in all endometrial cancer patients and an impressive 85% response rate in those with IHC 3+ expression. These results were particularly remarkable considering that the trial focused on recurrent cancer.

At the 14-month follow-up, the median progression-free survival had not been reached in the IHC 3+ group, further emphasizing the significance of the findings. Endometrial cancer treatment has seen exciting developments, such as the use of immunotherapy in the front-line setting for mismatch repair-deficient groups, but the DESTINY-PanTumor02 results highlight the importance of HER2 expression, particularly HER2 3+ expression, in this cancer type.

The data from the DESTINY-PanTumor02 trial has already been incorporated into the NCCN guidelines, and there is hope for tumor-agnostic approval based on these results. Dr. Salani's enthusiasm underscores the potential impact of these findings on the management of endometrial cancer.

Summary generated by Claude AI.